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Abstract 
 
Under pathophysiological conditions, infiltration of leukocyte plays a key role in the progression of the 
neuroinflammatory reaction in the CNS. Prostaglandin E2 (PGE2) is known to accumulate at lesion sites of 
the post-ischemic brain. Although post-ischemic treatments with cyclooxygenase-2 inhibitors reduce blood-
brain barrier (BBB) leukocyte infiltration, the direct effect of PGE2 on BBB has not been fully implemented. 
Therefore, the direct effect of increasing PGE2 infusion on translocation of labeled albumin into the brain 
was assessed. Under anesthesia rats were drilled stereo-taxicaly a burr hole in the right forebrain and PGE2 
was infused into the forebrain and the hole was occluded. The animals were then injected with fluorescent 
labeled albumin (FA), via internal right jugular vein and decapitated at different infusion time points. The 
forebrain was removed and each forebrain hemisphere was homogenized and fluorescence intensities were 
measured in the supernatant. The fluorescence intensities measured in the right and left forebrain 
hemispheres of the control group (0.0 µg PGE2) were almost identical. Four hours after infusion of PGE2 at 
doses higher than 250 µg, fluorescence intensity increased in the right forebrain supernatant, even if it was 
not statistically significant. The fluorescence intensity was detectable in the brain supernatant 4 h after 
infusion of PGE2 in doses higher than 250 µg PGE2. The highest fluorescence intensity was 16 h after 
infusion of 500 µg PGE2, which returned to near control values after 48 h. Increased fluorescence intensity in 
the brain following PGE2 infusion is concluded to be associated with disruption of the BBB. 
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INTRODUCTION 
 
Inflammation is one of the mechanisms 
known to participate in the progression of 
brain injury (1,2). A large number of studies 
indicate that blockade of the neuroin-
flammatory process considerably reduces 
ischemic brain injury (3-5). Prostaglandin E2 
(PGE2), one of the most likely candidates for 
the manifestation of the inflammation, is 
known to be accumulated at the lesion sites of 
the post-ischemic brain (1,6,7). These 
observations have been confirmed by 
biochemical studies that reported a significant 
increase in the expression of the PGE2 
synthesizing enzyme, cyclooxygenase (COX-
2), following ischemia (8-10). However, there 
is a debate on the specific role of PGE2 in 
cerebral ischemia (1). A recent study has 
found beneficial effects (11), another report 
claimed harmful (12), and an article reported 
PGE2 did not affect ischemic brain injury (13). 
However, several lines of evidence indicated 
that after the onset of ischemia, there is a 
significant disruption of the blood-brain 
barrier (BBB), followed by a massive 
infiltration of leukocytes (3,14,15). These 
reports suggested that disruption of BBB 
might be the main cause of neuroinflammatory 
process in the brain. While it is becoming clear 
that increased expression of COX-2 is 
associated with ischemic brain, it is by no 
means clear that a cause-and-effect 
relationship exists between the increased PGE2 
and BBB permeability directly. This study 
examines the time course and direct effects of 
increasing PGE2 infusion on translocation of 
labeled albumin into the brain. 
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MATERIALS AND METHODS 
 
Chemicals  
PGE2 (Prostin E2, 10 mg/ml) was purchased 
from Upjohn (Puurs Belgium), fluorescein 
isothiocyante isomer 1 (FITC), Sephadex G-25 
and rat serum albumin were procured from 
Sigma (Poole, Dorset, UK). Unless stated, all 
reagents were of the highest grade and made 
up in double glass-distilled water.  
 
Fluorescein-labeled rat serum albumin 
Preparation of fluorescein-labeled rat serum 
albumin was carried out by the method of 
Nargessi and coworkers (16). Equal volumes 
of FITC solution (1 mg/ml) and rat serum 
albumin solution (0.25 mg protein/ml) were 
mixed and stirred overnight at 4 °C. A 
Sephadex G-25 column (1.2 × 20 cm)                  
was then loaded by the FITC/serum                
albumin mixture.  
The entire fluorescein labeled albumin 
(FALB) band was identified by its 
fluorescence under the UV light in a dark 
room. The FALB band  eluted with 2 ml 
bicarbonate buffer (pH 9) and stored at -20 °C. 
Unconjugated FITC remained in the column. 
The pH of the labeled was adjusted to 7.4 and 
fluorescence intensity of FALB solution was 
measured using a Parkin-Elmer (Norwalk, CT) 
LSE spectrophotometer-fluorimeter with the 
excitation wavelength of 495 nm and an 
emission wavelength of 540 nm.  
 
Animals and preparations 
Eight-week-old male Wistar rats weighing 
200-220 g were purchased from the Pasteur 
Institute (Tehran, Iran). The animals were 
maintained with respect to the animal welfare 
regulation in animal house (6 rats in each 
group) in a regulated environment (25 ± 1 Ԩ; 
50 to 55% relative humidity; 12 h light/dark 
cycle), with free access to food (Pars Dam Co., 
Iran) and water. All procedures were approved 
by the Ethical Committee of the Isfahan 
University of Medical Sciences, and conducted 
in accordance with the ‘Principles of 
Laboratory Animal Care’ (National Institutes 
of Health publication no. 86-23, revised 1985). 
The animal surgery was performed between 
8-8:30 AM. Briefly rat was anesthetized by 
intramuscular injection of ketamine (100 
mg/kg) and xylazine (10 mg/kg) solution. The 
animals were then placed in a stereotaxic 
frame (Kopf Instruments, Tujunga, CA). The 
scalp and underlying soft tissues were 
removed. The animal was drilled 
stereotaxicaly a burr hole in the right midline 3 
mm anterior to bregma and 40 µl PGE2 
solutions (62.5, 125, 250 , 500 µg PGE2 
diluted in  normal saline) was infused slowly 
into the right forebrain by a fixed 
mycrosyrange for over 10 minutes, while only 
normal saline was infused into the right 
forebrain of the control group (sham treatment 
group). The hole was  occluded and the animal 
was closely monitored for 60 min. The animal 
was then injected with 1 ml fluorescein labeled 
albumin (100 µg albumin/ml ), via internal 
right jugular vein. The rats were killed by 
decapitation at different infusion time points: 
4, 8, 16, 24 and 48 h. The forebrain was then 
rapidly removed and each forebrain 
hemisphere was weighed up and homogenized 
in 5 ml of ice-cold saline Triton X-100. The 
homogenate was centrifuged for 10 min at 
16000 g and fluorescence intensity was 
measured in supernatant at the excitation 
wavelength of 495 nm and emission 
wavelength of 540 nm. Results were expressed 
relative to an arbitrary scale of fluorescence 
intensity. 
 
Statistical analysis 
Statistical analysis was performed using the 
Statistical Package of Social Science (SPSS) 
version 17. Data are presented as means ± 
standard deviation (SD). Experimental data 
from the right forebrain hemisphere are 
compared to their own left forebrain 
hemisphere values by pairing Student’s t-test. 
The level of significance was set at P<0.05. 
The corresponding parameters were also 
compared using analysis of variance 
(ANOVA). 
 
RESULTS 
 
Changes in BBB permeability to fluorescein-
labeled albumin were measured at right and left 
forebrain hemispheres after infusion of the range 
concentrations of PGE2 at different infusion time 
points. The results are summarized in Table 1. 
different infusion mmarized in Table 1. 
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Fig. 1. The time course of translocation of fluorescent labeled albumin. Animals were injected with 1 ml fluorescein 
labeled albumin (100 µg albumin/ml), via internal right jugular vein and PGE2 at doses of 500 µg was infused into the 
rat right brain hemisphere (see Method section), The fluorescence intensities were measured at infusion time points of 
4, 8, 16, 24, and 48 h after infusion in right (-●-) and left (-■-) forebrain supenatant of treatment groups and right (-○-) 
and left (-□-) sham groups.  
 
 
 
Fig. 2. Dose response curve of PGE2 with respect to the fluorescence intensities. Animals were injected with 1 ml 
fluorescein labeled albumin (100 µg albumin/ml), via their internal right jugular vein and PGE2 at dose ranges from 0 to 
500 µg were infused into the rat right brain hemisphere (see Method section), and the fluorescence intensities were 
measured 16 h after infusion at right (-●-) and left (-■-) brain supenatant.  
Table 1. The effect of PGE2 infusion on the translocation of fluorescein-labeled albumin into blood brain barrier. 
Time/Brain Region 
                                                PGE2 Doses (µg) 
0 62.5 125 250 500 
4 h/ Right 275 ± 43 286 ± 28 302 ± 71 325 ± 65 369 ± 43 
4 h/Left              241 ± 41 270 ± 23 281 ± 48 290 ± 62 300 ± 45 
8 h/ Right          276 ± 45 324 ± 26 380 ± 51* 439 ± 58*# 460 ± 66*# 
8 h/Left            245 ± 27 276 ± 16 309 ± 52 321 ± 41* 379 ± 78* 
16 h/Right        271 ± 39 495 ± 43*# 536 ± 29*# 623 ± 88*# 699 ± 68*# 
16 h/Left          239 ± 27 336 ± 24 374 ± 42* 409 ± 61* 485 ± 72* 
24 h/Right 268 ± 45 511 ± 27*# 573 ± 80*# 658 ± 29*# 699 ± 98*# 
24 h/left 231 ± 38 339 ± 58 383 ± 28* 422 ± 11* 496 ± 71* 
48 h/Right 265 ± 40 334 ± 42 340 ± 60 384 ± 49# 421 ± 72* 
48 h/Left 242 ± 52 296 ± 41 299 ± 34 230 ± 22 376 ± 67 
Values are means of fluorescence intensities  ± SD of 8 separate experiments. *; Differences are significant at 
p<0.05 as compared with corresponding sham vales. #; Differences are significant at p<0.05 as compared with the 
left values. 
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The fluorescence intensities measured in the 
right and left forebrain hemispheres of the 
control group (0.0 µg PGE2) were almost 
identical. Four hours after infusion of PGE2 at 
doses higher than 250 µg (see method section) 
fluorescence intensity increased in the right 
forebrain supernatant, even if it was not 
statistically significant. However, the 
fluorescence intensities in the right forebrain 
suprnatant markedly increased 16 h after 
infusion of 500 µg PGE2, which returned to 
near control values after 48 h. The 
fluorescence intensities in left forebrain 
suprnatant increased compared to the sham 
operation group.  
Fig. 1 shows the time course of 
translocation of FALB after 500 µg PGE2 
infusion. The values of fluorescence intensities 
increased in the treatment groups 16 and 24 h 
after infusion compared to corresponding 
sham values (P<0.05). Four hours after 
perfusion, the levels of tissue fluorescence 
intensities increased greatly in right forebrain 
compared with the left forebrain supernatant. 
Fig. 2 compares the fluorescence intensities 
measured in the suprnatants prepared from 
right and left brain hemispheres 16 h after 
infusion of different doses of PGE2 (62.5, 125, 
250 and 500 µg). As it can be seen the 
fluorescence intensities are significantly higher 
in the suprnatants prepared from right 
forebrain (P<0.05). The results indicated that 
translocation of FALB is dose dependent with 
respect to infeusion of PGE2, noticeably FALB 
would be augmented with doses of PGE2 
higher than 125 µg. 
 
DISCUSSION 
 
The present study assessed for the first time 
the contribution of PGE2 accumulation on 
BBB damage and infiltration of serum albumin 
in brain in an in vivo model. Furthermore, to 
the best of our knowledge, a detailed time 
course and dosages of PGE2 function, and its 
relation to the development of BBB disruption 
had not been previously investigated. Post-
ischemic inflammation has recently emerged 
as an important factor responsible for the 
development of the ischemic brain injury. In 
this regard, the present findings indicate that 
increasing PGE2 concentrations in right 
forebrain hemispheres resulted in BBB 
disruption and infiltration of the labeled 
albumin. The translocation of labeled albumin 
24 h after infusion of PGE2 is consistent with 
the observation of Krizanac-Bengez and 
coworkers who showed that the COX2 
inhibitor entirely protected BBB permeability 
in an in vitro BBB model using rat brain 
microvascular endothelial cells (17).  
Our findings, however, is not in agreement 
with the suggestion made by McCullough and 
colleagues that the disruption of the PGE2 
receptors aggravated neuronal death after 
transient forebrain ischemia, proposing that 
PGE2 has a neuroprotective effect on 
postischemic injury (18). In addition, the effect 
of PGE2 in the in vitro studies has been 
controversial, with results showing both toxic 
and protective effects on neuronal survival 
(11). However, Interpretation of these results, 
is difficult in part due to the complexity and 
heterogeneity of the brain regions with 
multiple actions of PGE2  receptors and 
treatment protocols. A potential link between 
PGE2 expression and PGE2 synthesis, which 
are involved in BBB damage, should be also 
considered as the main role of PGE2-mediated 
mechanism involved in brain cell 
inflammatory conditions (19,21). 
It is suggested that the restoration of 
cerebral blood flow after ischemia may 
provoke damage to the BBB, which may cause 
infiltration and aggravate brain edema (3). 
These observations shed more light into the 
specific role of the PGE2 function in ischemic 
brain injury, and might have important 
implications for the potential use of COX 
inhibitors or agents modulating PGE2 
synthesis in different clinical stages of cerebral 
ischemia. 
The model presented in this study 
demonstrated that PGE2 accumulation in the 
brain is responsible for the expansion of BBB 
disruption frankly, which is well-known factor 
for brain damage after cerebral ischemia 
(21,22). This is interpreted as being consistent 
with the COX-2 activation after ischemic brain 
injury (23,24). 
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CONCLUSION 
 
It is concluded that the cellular and 
microvascular response to PGE2 action is 
mediated through changes in the ultrastructure of 
the brain accompanied by an increase in BBB 
permeability. 
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